NCT02717156View on ClinicalTrials.gov

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

November 21, 2016

Primary Completion Date

November 21, 2025

Study Completion Date

November 21, 2026

Conditions
Stage IV Bladder Urothelial CarcinomaProstate CancerUrothelial Carcinoma
Interventions
PROCEDURE

Computed Tomography

Correlative studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Positron Emission Tomography

Correlative studies

BIOLOGICAL

Recombinant EphB4-HSA Fusion Protein

Given IV

Trial Locations (9)

22908

University of Virginia Cancer Center, Charlottesville

28277

Levine Cancer Institute-Carolinas Medical Center, Charlotte

66205

University of Kansas Cancer Center, Kansas City

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

90033

LAC+USC Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope, Duarte

92663

USC Norris Oncology/Hematology - Newport Beach, Newport Beach

95817

UC Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER